熱門資訊> 正文
Amylyx与Eiger达成协议，收购其针对的是GLGA的GLP-1靶向药物
2024-06-22 21:11
- Amylyx Pharmaceuticals (NASDAQ:AMLX) has signed an agreement with Eiger BioPharmaceuticals (OTC:EIGRQ) to acquire the rights to the latter’s Phase 3-ready GLP-1 receptor antagonist, Avexitide.
- Cambridge, Massachusetts-based Amylyx (AMLX) has agreed to pay $35.1M plus other payments for the acquisition, the company announced in an SEC filing late Friday.
- The experimental peptide therapy designed to bind with GLP-1 receptor on pancreatic cells has already undergone Phase 2 trials for the metabolic diseases congenital hyperinsulinism (HI) and post-bariatric hypoglycemia (PBH).
- The FDA has granted Avexitide rare pediatric disease designation in addition to breakthrough therapy designation in HI, and orphan drug designation in hyperinsulinemic hypoglycemia, which includes HI.
- The agreement is subject to multiple conditions, including approval from a Texas bankruptcy court, where Eiger (OTC:EIGRQ) has filed for Chapter 11 bankruptcy protection.
More on Amylyx, Eiger, etc.
- Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript
- Amylyx Pharmaceuticals Q1 2024 Earnings Preview
- Amylyx down 6% despite encouraging phase 2 data on rare disorder drug
- Seeking Alpha’s Quant Rating on Amylyx Pharmaceuticals
- Historical earnings data for Amylyx Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
